Quantcast
Last updated on April 23, 2014 at 19:54 EDT

Latest Quinazolines Stories

2014-04-14 12:34:34

RIDGEFIELD, Conn. and INDIANAPOLIS, April 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes (T2D). If granted approval by the FDA, this combination will bring together, for the first time into...

2014-04-09 10:43:30

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for...

2014-03-26 11:23:23

Presentations at the 4th European Lung Cancer Conference A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress. For decades, scientists and doctors thought immunotherapy –treatments that harness the immune system to fight a disease-- was of marginal benefit in lung cancer, says Jean-Charles Soria, Institute Gustave Roussy in Paris, France. However a...

New Combo Therapy Shows Promise For Cervical Cancer Treatment
2014-03-10 12:12:44

Bret Smith for redOrbit.com - Your Universe Online A team of Brazilian scientists has identified a promising new combination treatment that targets cervical cancer, according to a new report published in the journal Cancer. Patients with locally-advanced cervical cancer are typically prescribed cisplatin-based chemoradiation therapy (CRT), yet the benefits of this treatment have largely gone unresearched since the late 1990s, the study authors claimed. In search of a new treatment...

2013-12-12 12:27:19

NSCLC Treatment Will Become Increasingly Personalized Due to Emergence of Novel Targeted Therapies with Companion Diagnostic Tests, According to Findings from Decision Resources BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry of twelve new therapies into the non-small-cell lung cancer (NSCLC) drug market will drive the market's growth from $4.9...

2013-12-09 12:25:58

Approximately Three-Quarters of Gilotrif Nonprescribers Anticipate Prescribing Gilotrif Within the Next Six Months, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, one month post-launch in the United States, more than a quarter of surveyed U.S. medical oncologists have prescribed Boehringer Ingelheim's...

2013-11-07 12:28:12

New targeted treatment delays lung cancer tumour progression and improves disease related symptoms versus standard chemotherapy(i) BURLINGTON, ON, Nov. 7, 2013 /CNW/ - Boehringer Ingelheim (Canada) Ltd. announced today that Health Canada has approved GIOTRIF(®) (afatinib) tablets for oral use, as a new treatment for Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic (including cytologically proven pleural effusion) adenocarcinoma of...

2013-11-04 23:19:01

Reportbuyer.com just published a new market research report: PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022. London (PRWEB) November 04, 2013 PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch...

2013-11-04 23:04:31

Reportbuyer.com just published a new market research report: PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) November 04, 2013 PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of...

2013-10-31 12:25:01

Interviewed Payers Say Biomarker-Driven Prescribing is an NSCLC Market Access Lever, But Optimal Pivotal Trial Design is Also Key, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 31, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed medical oncologists across the EU5 (France, Germany, Italy, Spain, and the United Kingdom) currently prescribe the...